Neumora Therapeutics is expected to report a Q3 2026 loss of $0.19 per share on $0.00 million in revenue, while the stock currently trades at $16.12 compared to a $24.50 analyst average price target. Investors are primarily focused on the clinical progress of navacaprant, the company's lead Phase 3 candidate for Major Depressive Disorder (MDD).

Analysts are closely monitoring R&D expenses, estimated at $58.2 million for the quarter, to evaluate the company's capital allocation as it advances its neuropsychiatry pipeline. This report follows the completion of enrollment for key trials, making regulatory milestones and cash runway the critical drivers for Neumora’s valuation heading into 2027.